BlossomHill Therapeutics Announces FDA Alignment on Phase 2 Dose for BH-30643
BlossomHill Therapeutics has reached alignment with the U.S. Food and Drug Administration on a 50 mg twice-daily dose for the Phase 2 trial of its OMNI-EGFR inhibitor, BH-30643.